|Bid||15.50 x 800|
|Ask||15.52 x 800|
|Day's Range||15.31 - 15.68|
|52 Week Range||14.35 - 26.10|
|Beta (3Y Monthly)||-0.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.58|
WALTHAM, Mass., Feb. 19, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 38.78% and -2.17%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had a loss of 64 cents per share. Losses, adjusted to account for discontinued operations, were 60 cents per share. The results beat Wall Street expectations. ...
Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM,.
WALTHAM, Mass., Jan. 30, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2018 financial results will be released on.
AMAG Pharmaceuticals, Inc. (AMAG) announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG adds ciraparantag to its development portfolio. Ciraparantag is in development as a single dose, ready-to-use solution for use in patients treated with novel oral anticoagulants (NOACs) or low molecular weight heparin (LMWH) when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding.
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Christine Moulton Clemson, Ph.D., M.S.C.I., as vice president, medical affairs, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Clemson will serve as a medical lead for AMAG’s women’s healthcare products. “Christine brings broad medical affairs, scientific, and functional leadership experience that will greatly contribute to our expanding medical affairs organization and AMAG’s goal to further grow as a development company,” said Dr. Robinson.
AMAG Pharmaceuticals, Inc. (AMAG) today announced preliminary unaudited fourth quarter and full year 2018 financial results and provided 2019 financial guidance. "In 2018, we achieved several key milestones including receiving two approvals from the U.S. Food and Drug Administration (FDA), launching both the Makena subcutaneous auto-injector and Feraheme broad label, and receiving FDA acceptance of our new drug application for VyleesiTM (bremelanotide).
In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.
WALTHAM, Mass., Dec. 19, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, president and chief executive officer, will present at the.
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG will acquire global rights to ciraparantag, a next generation anticoagulant reversal agent, further enhancing its development pipeline and leveraging AMAG’s expertise in hematology.
Does the December share price for AMAG Pharmaceuticals Inc (NASDAQ:AMAG) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
WALTHAM, Mass., Nov. 29, 2018 -- As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG.